State of NJ SAGE

The State of New Jersey has an electronic grant management system called SAGE (System for Administering Grants Electronically).

Learn More

Supported by Public Law

Newborn screening is supported by Chapter 24 of the Public Laws of 1988, N.J.S.A. 26:2-110 and N.J.S.A. 26:2-111, New Jersey Administrative Code, Title 8, Department of Health, Chapter 18, and this bill.

Newborn Bloodspot Screening

Newborn screening is an essential public health function designed to screen, identify and link babies to comprehensive, community based, culturally competent, family centered services.

Mission Statement

The mission of the Newborn  Bloodspot  Screening Follow-up Program is to promote and protect the health of all newborns identified as having out-of-range results by the Newborn Screening Laboratory.

We communicate with parents, physicians, specialists and others to ensure that identified babies have access to timely and quality diagnostic testing and comprehensive care.  

The History of Bloodspot Screening

In 1964 newborn screening for Phenylketonuria (PKU) was mandated.  Legislation and advances in technology have contributed to great growth in the newborn screening panel.  Today, NJ screens for 61 disorders with continued growth expected.

Newborn Screening Advisory Review Committee (NSARC)

New Jersey law requires that every baby born in New Jersey be screened for disorders that can cause serious health problems. Therefore, the Commissioner of Health has established a Newborn Screning Advisory Review Committee (NSARC) to annually review the disorders included in the Newborn Screening program.

Purpose of the Committee

To assist the DOH in reviewing newborn screening policies and procedures and advise the Commissioner of Health on matters affecting newborn bloodspot screening (NBS) processes in New Jersey. 

The Committee meets twice a year in the month of May and November.

Learn More



Last Reviewed: 5/17/2024